Glenmark Pharmaceuticals Limited
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Glenmark Pharmaceuticals Limited's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 3% to $118,130,970,000. Profit margin reached -13%. Total operating expenses were $46,952,560,000.
Profit Margin
| 2010 | 25.00B | 3.31B | 13.24% |
|---|---|---|---|
| 2011 | 29.49B | 4.57B | 15.52% |
| 2012 | 40.20B | 4.64B | 11.55% |
| 2015 | 65.21B | 4.75B | 7.29% |
| 2016 | 75.03B | 7.02B | 9.36% |
| 2018 | 89.43B | 7.74B | 8.66% |
| 2019 | 97.05B | 8.91B | 9.19% |
| 2021 | 108.06B | 9.70B | 8.98% |
| 2022 | 121.74B | 9.41B | 7.74% |
| 2024 | 118.13B | -15.01B | -12.71% |
GLENMARK.NS Income Statement (2010 – 2023)
| 2023 | 2021 | 2020 | 2018 | 2017 | 2015 | 2014 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 118.13B | 121.74B | 108.06B | 97.05B | 89.43B | 75.03B | 65.21B | 40.20B | 29.49B | 25.00B |
Cost of revenue | 85.53B | 44.59B | 37.43B | 34.07B | 31.09B | 23.97B | 19.66B | 13.45B | 9.91B | 10.19B |
Gross profit | 32.59B | 77.14B | 70.62B | 62.97B | 58.34B | 51.05B | 45.55B | 26.75B | 19.57B | 14.81B |
Operating exp. | ||||||||||
Research and development | 12.25B | 12.78B | 13.18B | 14.48B | 12.25B | 8.17B | 6.01B | 0 | 0 | 772.75M |
Selling and marketing | 10.92B | 8.96B | 9.79B | 8.70B | 7.62B | 6.58B | 5.58B | 0 | 0 | 0 |
Total operating expenses | 46.95B | 58.74B | 53.46B | 52.58B | 45.70B | 39.57B | 36.36B | 20.49B | 13.19B | 9.33B |
Operating income | 6.50B | 18.40B | 17.16B | 15.89B | 13.43B | 11.76B | 7.83B | 6.25B | 6.38B | 5.47B |
Other income (expenses), net | -6.13B | -3.98B | -2.82B | 407.34M | -1.96B | -1.71B | -1.88B | -1.37B | 1.56B | 1.64B |
Income before tax | 364.95M | 14.41B | 13.82B | 12.57B | 10.66B | 10.04B | 5.94B | 4.88B | 4.81B | 3.83B |
Income tax expense | 18.67B | 4.47B | 4.12B | 3.66B | 2.92B | 3.02B | 1.19B | 237.84M | 237.2M | 528.65M |
Net income | -15.01B | 9.41B | 9.70B | 8.91B | 7.74B | 7.02B | 4.75B | 4.64B | 4.57B | 3.31B |
Earnings per share | ||||||||||
Basic EPS | -53.22 | 33.37 | 34.38 | 31.6 | 27.44 | 25.01 | 17.52 | 17.03 | 16.78 | 12.4 |
Diluted EPS | -53.22 | 33.37 | 34.38 | 31.6 | 27.43 | 25 | 17.52 | 17.01 | 16.76 | 12.4 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |